Brought to you by 
Servier options rights to up to six Cellectis cancer projects; deal terms amended
30 Jan 2023
Executive Summary
Oncology company Cellectis SA granted Servier SA options for exclusive rights to up to six of its preclinical cancer projects, including lead candidate UCART19, an allogenic CD19 T-cell therapy for leukemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Servier options rights to up to six Cellectis cancer projects; deal terms amended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice